[Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
OBJECTIVE
To analyze the subtypes of primary diffuse large B cell lymphoma of the central nervous system (CNS DLBCL) and to explore the relationship between the subtype classification and prognosis.


METHODS
Immunohistochemical staining was used to determine the expression of CD20, CD3, CD10, Bcl-6, Mum-1, CD5, Bcl-2, Ki-67, FOXP-1, GCET-1, BLIMP-1 and LMO-2 antigens on paraffin-embedded sections of 47 cases. Hans, Choi and Tally subtypes were classified, and univariate and multivariate analyses were used to elucidate the relationship between the subtypes and prognosis.


RESULTS
In the 47 cases, the expression of Bcl-2 in the tumor cells was 46.8%, CD10 4.3%, Bcl-6 70.2%, Mum-1 53.2%, GCET-1 36.2%, BLIMP-1 4.3%, FOXP-1 63.8% and LMO-2 19.2%. The positive rate of Ki-67 was 30% to 95%, with a median of 80%, of which 12 cases (25.5%) was > or = 90%. The Hans subtype classification showed 16 cases (34.0%) were of GCB type and 31 cases (66.0%) of non-GCB type. The Choi subtype classification showed 16 cases (34.0%) were of GCB type and 31 cases (66.0%) of ABC type. The Tally subtype classification showed 6 cases (12.8%) were of GCB type and 41 cases (87.2%) of non-GCB type.


CONCLUSIONS
The results of this study show that there is no significant correlation between the three subtypes and prognosis. The prognosis is correated with post-operative radiotherapy, chemotherapy and MTX therapy.
Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China.
Min
M
Min
Li
L
Lin
Cheng-Feng
CF
Bi
Xiao-Qing
XQ
Wang
Tian-You
TY
Luo
Sha
S
Zhao
Wen-Yan
WY
Zhang
Wei-Ping
WP
Liu
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000145:classification* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D051858:Forkhead Transcription Factors / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D050835:Interferon Regulatory Factors / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D060588:LIM Domain Proteins / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D015260:Neprilysin / Q000378:metabolism; D000074462:Positive Regulatory Domain I-Binding Factor 1; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000378:metabolism; D012097:Repressor Proteins / Q000378:metabolism; D012189:Retrospective Studies; D015843:Serpins / Q000378:metabolism; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult; D000099218:Interferon Regulatory Factor-4
D048868:Adaptor Proteins, Signal Transducing; D003520:Cyclophosphamide; D004317:Doxorubicin; D051858:Forkhead Transcription Factors; D050835:Interferon Regulatory Factors; D019394:Ki-67 Antigen; D060588:LIM Domain Proteins; D008727:Methotrexate; D009363:Neoplasm Proteins; D015260:Neprilysin; D000074462:Positive Regulatory Domain I-Binding Factor 1; D011241:Prednisone; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6; D012097:Repressor Proteins; D015843:Serpins; D014750:Vincristine; D000099218:Interferon Regulatory Factor-4; C486626:FOXP1 protein, human; C085117:LMO2 protein, human; C476825:SERPINA9 protein, human; C087042:PRDM1 protein, human